Hospital Regional Universitario de Málaga-ko ikertzaileekin lankidetzan egindako argitalpenak (12)

2023

  1. TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck

    Frontiers in Oncology, Vol. 13

2021

  1. SEOM clinical guideline for management of adult medulloblastoma (2020)

    Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 940-947

2018

  1. Correction to: SEOM clinical guidelines for anaplastic gliomas (2017) (Clinical and Translational Oncology, (2018), 20, 1, (16-21), 10.1007/s12094-017-1762-7)

    Clinical and Translational Oncology

  2. SEOM clinical guidelines for anaplastic gliomas (2017)

    Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 16-21

2017

  1. Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification

    Neuro-Oncology, Vol. 19, Núm. 11, pp. 1522-1531

2016

  1. GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status

    Clinical and Translational Oncology, Vol. 18, Núm. 8, pp. 805-812

  2. Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma

    Anti-Cancer Drugs, Vol. 27, Núm. 2, pp. 133-137

2014

  1. Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry

    Journal of Neuro-Oncology, Vol. 116, Núm. 2, pp. 413-419

  2. Erratum: Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry [J Neurooncol, 116, (2014), 413-419, DOI 10.1007/s11060-013-1316-y]

    Journal of Neuro-Oncology

  3. Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain

    Clinical and Translational Oncology, Vol. 16, Núm. 3, pp. 273-279

2012

  1. Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO)

    Anti-Cancer Drugs, Vol. 23, Núm. 6, pp. 659-665

2011

  1. Melanoma heredo-familiar

    Revisiones en Cancer, Vol. 25, Núm. 4, pp. 166-171